Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

Demand for weight-loss drugs, including GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, has surged in the United States. In May 2024, a KFF Health Tracking Poll found that approximately 6 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients. Under the new option ...

In 'Diet, Drugs, and Dopamine,' former FDA Commissioner David A. Kessler offers a comprehensive guide to weight loss.

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new analysis finds. Newer medications, such as Mounjaro and Wegovy, exhibit both more ...